tradingkey.logo

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

ReutersMay 23, 2025 12:40 PM

- SpringWorks Therapeutics Inc SWTX.O:

  • SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR MIRDAMETINIB FOR TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

  • SPRINGWORKS THERAPEUTICS INC: DECISION FROM EUROPEAN COMMISSION EXPECTED IN Q3 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI